Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Boyd is a physician scientist, Associate Professor of Pathology and Endowed Faculty Scholar in Allergy and Immunology at Stanford University. The Boyd laboratory uses high-throughput DNA sequencing and single-cell experiments to analyze human immune responses to infection and vaccination, as well as immunological disorders such as food allergy and immunodeficiency. Many of the laboratory’s projects analyze the responses of B cells and the genetics and functional roles of antibodies in health and disease. He received bachelor's degrees in Biochemistry at the University of Manitoba, and English Literature at Oxford University, where he was a Rhodes Scholar. He obtained his M.D. from Harvard Medical School and Ph.D. from MIT, followed by pathology residency, hematopathology fellowship, and postdoctoral research work at Stanford University. He is a recipient of the Presidential Early Career Award for Scientists and Engineers, among other honors. Dr. Boyd has consulted as an expert witness in patent disputes related to antibody technologies and antibody drugs.
Our goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with functional assays. Our main focus has been defining clonal lineages of B cells and their antigen specificity in clinical samples from healthy individuals undergoing vaccination or responding to infection, as well as in patients with immune-mediated diseases such as food allergy. Other areas of active research are the B cell responses to HIV, immune deficiencies related to human aging, and transplant immunology.
Integrated Whole-Genome Analysis of Hematologic Disorders
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the
disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is
to analyze all of the genes in the diseased and normal skin sample. By comparing the results
of the diseased sample and normal skin cells and the results of the two types of genetic
information (DNA and RNA), we should be able to identify genetic changes that are important
for the initiation, progression, or treatment response of that particular disorder.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jason D Merker, 650-922-1885.
View full details